Skip to main content

Table 1 Patients characteristics

From: Effects of prolonged direct hemoperfusion using a polymyxin B immobilized fiber cartridge on interleukin-6 concentration in patients with septic shock: a prospective exploratory trial

  PMX-DHP-2h (n = 7) PMX-DHP-12h (n = 16) P value
Age, year, median (IQR) 75 (66–81) 78 (60–84) 0.92
Male, number (%) 4 (57%) 6 (38%) 0.65
Body mass index, median (IQR) 20.2 (18.8–22.2) 22.3 (21.6–25.7) 0.04
APACHE II score at ICU admission, median (IQR) 21 (17–28) 23 (18–31) 0.64
SOFA score at the day of the first PMX-DHP session, median (IQR) 11 (7–11) 10 (8–14) 0.84
Comorbidity
 Immunosuppression, number (%) 2 (29%) 4 (25%) 1.00
 Chronic dialysis, number (%) 1 (14%) 2 (13%) 1.00
 Home oxygenation therapy, number (%) 0 (0%) 1 (7%) 1.00
 Decompensate heart failure, number (%) 1 (14%) 1 (7%) 0.53
 Diabetes mellitus, number (%) 0 (0%) 3 (19%) 0.53
Site of infection    0.11
 Abdomen, number (%) 3 (43%) 13 (81%)  
 Urinary tract, number (%) 2 (29%) 1 (6%)  
 Others, number (%)* 2 (29%) 2 (13%)  
Causative organisms    0.10
 Gram-negative rod, number (%) 2 (29%) 1 (6%)  
 Mixed, number (%) 1 (14%) 7 (44%)  
 Gram-positive bacteria, number (%) 2 (29%) 3 (19%)  
 Fungi, number (%) 0 (0%) 1 (6%)  
 Unknown, number (%) 2 (29%) 4 (25%)  
Number of PMX-DHP session    1.00
 1 session, number (%) 3 (43%) 6 (38%)  
 2 sessions, number (%) 4 (57%) 10 (62%)  
Treatment in ICU
 Continuous renal replacement therapy, number (%) 1 (15%) 8 (50%) 0.18
 Mechanical ventilation, number (%) 7 (100%) 16 (100%) 1.00
 Low dose steroid, number (%) 5 (71%) 14 (87%) 0.56
Laboratory test
 White blood cell, 102/mcl, median (IQR) 89 (14–121) 88 (34–144) 0.53
 C reactive protein, mg/dl, median (IQR) 9.1 (6.1–18.9) 15.9 (8.0–24.4) 0.15
 Total bilirubin, mg/dl, median (IQR) 0.9 (0.7–1.5) 0.8 (0.5–2.0) 0.81
 Creatinine, mg/dl, median (IQR) 1.8 (0.9–2.6) 1.6 (1.2–2.5) 0.76
 PT-INR, median (IQR) 1.3 (1.1–1.4) 1.3 (1.2–1.7) 0.71
 Lactate, mmol/l, median (IQR) 5.1 (1.4–8.5) 3.8 (2.0–7.5) 0.84
  1. PMX-DHP-2h polymyxin direct hemoperfusion for 2 h, PMX-DHP-12h polymyxin direct hemoperfusion for 12 h, IQR interquartile range, APACHE II acute physiology and chronic health evaluation, SOFA sequential organ failure assessment, ICU intensive care unit, PT-INR prothrombin time-international normalized ratio
  2. *Other site of infection includes infectious endocarditis, necrotizing fasciitis, neutropenic fever, and septic shock of unknown origin (each site is 1 case)
  3. Laboratory tests were performed on the day of the first PMX-DHP session. The serum lactate concentration noted here was the maximum value observed from the diagnosis of septic shock to the initiation of PMX-DHP administration